Small-Cap Healthcare: A Comparison Between STAAR Surgical and Lifevantage

In the realm of small-cap healthcare enterprises, a comparison between STAAR Surgical and Lifevantage becomes an intriguing exercise. The key variables for this comparative inspection encompass elements like expert analyses, risk factors, institutional holdings, business valuation, earnings, and financial gain.

When analyzing risk and volatility, STAAR Surgical displays a beta of 0.74, indicating its stock price is approximately 26% less volatile relative to the S&P 500. On the other hand, Lifevantage presents a beta of 0.39, illustrating its stock price’s volatility is lower by 61% in comparison to the S&P 500.

Shifting our attention to profitability, we delve into the net margins, return on equity, and return on assets of both firms. The net margins of STAAR Surgical stands at -42.45%, with a return on equity and assets reported as -16.11% and -12.54% respectively. Contrarily, Lifevantage records a 4.29% net margin, with return on equity and assets at 33.75% and 15.26%.

As part of our comparison, let us examine the gross revenue, earnings per share (EPS), and valuation of STAAR Surgical and Lifevantage. STAAR Surgical boasts a gross revenue of $313.90 million, with earnings per share valued at ($1.93). The price-to-earnings ratio stands at -14.35. On the other hand, Lifevantage, with gross revenue of $228.53 million and an EPS of $0.74, registers a price-to-earnings ratio of 15.04.

With lower gross revenue yet higher earnings, Lifevantage challenges its counterpart. Further, STAAR Surgical’s current trading situation suggests a lower price-to-earnings ratio compared to Lifevantage, indicating affordability relative to the two stocks.

Investigating ownership pattern, institutional investors possess 96.7% of STAAR Surgical shares, while these investors make up 35.3% of Lifevantage’s share. Meanwhile, STAAR Surgical insiders own approximately 0.6% of company shares compared to Lifevantage insiders who hold about 20.7%.

The high percentage of institutional ownership generally indicates robust faith of stakeholders in the longevity and growth potential of a stock. Strong institutional belief translates to predictions of long-term stock appreciation.

Analyzing expert opinions, we present an aggregation of recent ratings and price targets for STAAR Surgical and Lifevantage. STAAR Surgical holds a consensus target price of $20.67, predicting a potential drop of 25.39%. In contrast, Lifevantage has a consensus target price of $30.50, signaling a possible increase of 174.03%.

Factoring in Lifevantage’s superior consensus rating and higher potential ascension, analysts favor Lifevantage over STAAR Surgical in terms of investment potential. A comparative analysis of 14 variables shows Lifevantage outperforming STAAR Surgical in 10 categories.

STAAR Surgical Company, alongside its affiliated entities, is involved in conceptualizing, executing, producing, and advertising implantable ocular lenses and complementary lens delivery systems. These products primarily serve to rectify optical disorders such as myopia, hyperopia, astigmatism, and presbyopia.

STAAR Surgical operates globally, with direct sales areas in regions like the United States, Japan, Germany, Spain, Canada, the U.K., and Singapore. Additionally, through a network of representatives and independent distributors, the company holds a presence in China, Korea, India, France, Benelux, Italy, and other international territories.

LifeVantage Corporation specializes in identifying, researching, formulating, and selling advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. Some products include Protandim, LifeVantage Omega+, LifeVantage ProBio, PhysIQ, LifeVantage IC Bright, Petandim for Dogs, and Axio.

LifeVantage also markets a diverse range of anti-aging skincare innovations under the LifeVantage TrueScience brand name, alongside bath, body, and targeted relief products. These offerings include body lotion, body wash, body butter, deodorant, soothing balm, and body rub.

Operating through independent distributors, LifeVantage spans across various nations such as the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, U.K., the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. With its inception in 2003, the corporation’s headquarters is stationed in Lehi, Utah.